@article{17b3bfe362eb4354b36ae1990b28828f,
title = "Protein-protein interactions as therapeutic targets in neuropsychopharmacology",
author = "Reilly, {Matthew T.} and Cunningham, {Kathryn A.} and Amarnath Natarajan",
note = "Funding Information: This work was supported by the NIH/NIDA Intramural Research Program. The authors declare that except for income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. ..................................................................... Beardsley PM, Howard JL, Shelton K, Carroll FI (2005). Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 183: 118–126. Emrich HM, Vogt P, Herz A (1982). Possible antidepressive effects of opioids: action of bupre-norphine. Ann NY Acad Sci 398: 108–112. Hurd YL, Herkenham M (1993). Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13: 357–369. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-in-duced behavioral responses. J Neurosci 23: 5674–5683. Nestler EJ, Carlezon Jr WA (2006). The mesolimbic dopamine reward circuit in depression. Biol Psy-chiatry 59: 1151–1159. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986). Psychotomimesis mediated by kappa opiate re-ceptors. Science 233: 774–776. Shippenberg TS, Zapata A, Chefer VI (2007). Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116: 306–321.",
year = "2009",
month = jan,
doi = "10.1038/npp.2008.167",
language = "English (US)",
volume = "34",
pages = "247--248",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",
}